ArticleMolecular genetics & genomic medicine2026
Mutation Spectrum and Novel Rare Variants in a Han Chinese Hearing Loss Cohort Using a Tiered Sequencing Strategy.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHereditary hearing loss is a genetically heterogeneous disorder posing challenges for molecular diagnosis. This study aimed to characterize the mutation spectrum, including rare and previously unreported variants, using a tiered strategy in a Han Chinese cohort from Southwest China.
methodsIn this retrospective study, 43 patients underwent targeted hotspot screening, followed by whole-exome sequencing in 11 patients with no hotspot variants detected. Variants were annotated and interpreted according to American College of Medical Genetics and Genomics guidelines.
resultsInitial hotspot screening established molecular diagnoses in 23 patients based on seven pathogenic or likely pathogenic variants in MT-RNR1, GJB2, and SLC26A4. Whole-exome sequencing identified six additional rare variants in CDH23, ILDR1, OTOF, and SLC12A2, and established two diagnoses involving ILDR1 and CDH23. A previously unreported SLC12A2 missense variant, c.2936A>G (p.Glu979Gly) was identified as a variant of uncertain significance and retained as a candidate finding. CDH23 c.5311C>T (p.Arg1771Ter) has not previously been reported in Han Chinese patients with hearing loss, to our knowledge.
conclusionsThese findings expand the mutation spectrum of hereditary hearing loss in a Han Chinese cohort from Southwest China and highlight the practical value of a tiered testing strategy integrating targeted hotspot screening with whole-exome sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.